To our knowledge no in vivo studies has been carried out comparing the tumor growth in an IFNLR1-deficient mouse model of epithelial origin or the use of recombinant Pegulated-IFNλ to evaluate the potential antitumorigenic role of drug-targeting the IFNλ-signaling pathway. Here, IFNLR1 is linked to neoplasm.